The researchers found that a promising virus treatment provided a double blow to cancer, and that it was possible to secretly approach an undetected tumor by riding a blood cell. Related papers are published in the journal Science Translational Medicine. (Literature Reading: Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients)
In this new study, researchers from the University of Leeds and the Cancer Institute (ICR) in the United Kingdom revealed how the "hitchhiking" virus escaped antibodies in the bloodstream that might neutralize its anti-cancer properties.
The patient's results suggest that such viral therapy can be effectively injected into the patient's bloodstream in routine outpatient appointments - just like standard chemotherapeutic drugs - making it potentially suitable for the treatment of multiple types of cancer.
Reovirus is a promising new approach to cancer treatment. It can attack cancer through two fronts. Not only can the virus kill cancer cells directly, but it can also trigger an immune response like a vaccine to help clear residual cancer cells.
Many current reovirus trials are underway, including several trials in the United Kingdom led by the University of Leeds and the Cancer Institute. However, until now, doctors have not been able to determine the best way to deliver this experimental treatment. Although it is possible to inject the virus directly into the tumor, this is still a relatively complicated process requiring considerable technical expertise. This delivery method also makes it difficult to treat tumors deep in the human body such as the liver, lungs, pancreas, and stomach.
Researchers have been concerned about the issue of intravenous injections of reovirus that, like standard chemotherapeutics, may not be able to reach the site of their intended treatment. They believe that the antibodies in the blood will clear and neutralize the virus before it reaches the intended target.
However, tests on a small group of patients now indicate that this is not the case. In fact, the virus not only maintains activity during the journey through the bloodstream, but also targets cancer cells without touching the surrounding healthy tissues.
Professor Alan Melcher of the University of Leeds was one of the co-leaders of the study and he received funding from the British Cancer Research Institute. He said: "It looks like the reovirus is far more intelligent than we thought. By carrying it on blood cells, the virus managed to escape from the body's natural immune response and reached its target without damage." It is very important to incorporate such viral treatments into clinical practice."
Dr Kevin Harrington, co-leader of the study, the Cancer Institute and the Royal Marsden NHS Trust, said: "Viral treatment like reovirus is showing real prospects in patient trials. This study has brought us The excellent news is that it would be possible to use simple injection into the bloodstream to deliver these treatments. If it can only be injected into the tumor will be an important obstacle to its widespread use, however studies have found that they can be carried Blood cells will probably make them suitable for a variety of cancers. We also confirmed that reovirus specifically targets cancer cells and avoids normal cells, and we expect that this will mean fewer side effects for patients."
Ten advanced colon cancers have spread to the liver and patients who should be treated surgically participated in the study. As an outpatient, all patients were given 5 doses of reovirus within weeks before surgery.
Blood tests shortly after treatment found active blood cells associated with blood cells. Subsequent samples showed that the free-riding virus did not stay on the cells for long, but was quickly cleared by the system.
When the researchers observed the fragments of tissues removed during the surgery for up to four weeks, they discovered "virus factories" and active viruses that were present in the tumor. This confirms that the reovirus was specifically passed to the cancer after it was injected into the bloodstream.
Dr Julie Sharp, Senior Director of Information Technology for Cancer Research at the United Kingdom, said: "This promising study shows that the reovirus can deceive the body's defense system to reach and kill cancer cells, indicating that it can be given to patients through simple injections. We look forward to seeing The progress of this research, and whether it will one day become part of standard cancer therapy."
In this new study, researchers from the University of Leeds and the Cancer Institute (ICR) in the United Kingdom revealed how the "hitchhiking" virus escaped antibodies in the bloodstream that might neutralize its anti-cancer properties.
The patient's results suggest that such viral therapy can be effectively injected into the patient's bloodstream in routine outpatient appointments - just like standard chemotherapeutic drugs - making it potentially suitable for the treatment of multiple types of cancer.
Reovirus is a promising new approach to cancer treatment. It can attack cancer through two fronts. Not only can the virus kill cancer cells directly, but it can also trigger an immune response like a vaccine to help clear residual cancer cells.
Many current reovirus trials are underway, including several trials in the United Kingdom led by the University of Leeds and the Cancer Institute. However, until now, doctors have not been able to determine the best way to deliver this experimental treatment. Although it is possible to inject the virus directly into the tumor, this is still a relatively complicated process requiring considerable technical expertise. This delivery method also makes it difficult to treat tumors deep in the human body such as the liver, lungs, pancreas, and stomach.
Researchers have been concerned about the issue of intravenous injections of reovirus that, like standard chemotherapeutics, may not be able to reach the site of their intended treatment. They believe that the antibodies in the blood will clear and neutralize the virus before it reaches the intended target.
However, tests on a small group of patients now indicate that this is not the case. In fact, the virus not only maintains activity during the journey through the bloodstream, but also targets cancer cells without touching the surrounding healthy tissues.
Professor Alan Melcher of the University of Leeds was one of the co-leaders of the study and he received funding from the British Cancer Research Institute. He said: "It looks like the reovirus is far more intelligent than we thought. By carrying it on blood cells, the virus managed to escape from the body's natural immune response and reached its target without damage." It is very important to incorporate such viral treatments into clinical practice."
Dr Kevin Harrington, co-leader of the study, the Cancer Institute and the Royal Marsden NHS Trust, said: "Viral treatment like reovirus is showing real prospects in patient trials. This study has brought us The excellent news is that it would be possible to use simple injection into the bloodstream to deliver these treatments. If it can only be injected into the tumor will be an important obstacle to its widespread use, however studies have found that they can be carried Blood cells will probably make them suitable for a variety of cancers. We also confirmed that reovirus specifically targets cancer cells and avoids normal cells, and we expect that this will mean fewer side effects for patients."
Ten advanced colon cancers have spread to the liver and patients who should be treated surgically participated in the study. As an outpatient, all patients were given 5 doses of reovirus within weeks before surgery.
Blood tests shortly after treatment found active blood cells associated with blood cells. Subsequent samples showed that the free-riding virus did not stay on the cells for long, but was quickly cleared by the system.
When the researchers observed the fragments of tissues removed during the surgery for up to four weeks, they discovered "virus factories" and active viruses that were present in the tumor. This confirms that the reovirus was specifically passed to the cancer after it was injected into the bloodstream.
Dr Julie Sharp, Senior Director of Information Technology for Cancer Research at the United Kingdom, said: "This promising study shows that the reovirus can deceive the body's defense system to reach and kill cancer cells, indicating that it can be given to patients through simple injections. We look forward to seeing The progress of this research, and whether it will one day become part of standard cancer therapy."
Fruit Powder,Vegetable Powder,Fruit Extract Powder,Natural Vegetable Powder
Xi'an JCF Herb Technology Development Co., Ltd , https://www.jcfherb.com